Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 pivotal study of XEN496, a Kv7 potassium channel modulator for the potential treatment of KCNQ2 epileptic encephalopathy

Trial Profile

A phase 3 pivotal study of XEN496, a Kv7 potassium channel modulator for the potential treatment of KCNQ2 epileptic encephalopathy

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Retigabine (Primary)
  • Indications Epilepsy
  • Focus Registrational; Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2018 According to a Xenon Pharmaceuticals media release, investigational new drug application is expected to be submitted in the first half of 2019.
    • 17 Sep 2018 New trial record
    • 06 Sep 2018 According to a Xenon Pharmaceuticals media release, based on the feedback from the U.S. Food and Drug Administration (FDA), the company plans to initiate this pivotal study is expected to start in mid 2019. Additional details like, trial design, dosing, and endpoints, the protocol development for this study are anticipated in the coming months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top